(Q46830766)

25 December 2017

title

Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan (English)

1 reference

25 December 2017

author name string

T Fietz

1

1 reference

25 December 2017

L Uharek

2

1 reference

25 December 2017

C Gentilini

3

1 reference

25 December 2017

A Muessig

4

1 reference

25 December 2017

K Rieger

5

1 reference

25 December 2017

O Marinets

6

1 reference

25 December 2017

D Sandrock

7

1 reference

25 December 2017

D L Munz

8

1 reference

25 December 2017

B Glass

9

1 reference

25 December 2017

E Thiel

10

1 reference

25 December 2017

I W Blau

11

1 reference

25 December 2017

publication date

1 January 2006

1 reference

25 December 2017

published in

Leukemia & Lymphoma

1 reference

25 December 2017

volume

47

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

59-63

1 reference

25 December 2017

Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Monoclonal antibody therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Radioimmunotherapy of non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500260478

10.1080/10428190500260478

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017